GlaxoSmithKline Provides Information to the Shareholders
October 08, 2021 at 02:40 pm IST
On October 8, 202, Chairman Jonathan Symonds said GlaxoSmithKline still plans to split its consumer division and increase the number of pharmaceutical experts and scientists on its board in 2022. In a call with investors Symonds said the UK pharmaceutical company will also name a new chair for its consumer business, which will be separated from its pharmaceutical and vaccines segments in mid-2022. The chairman, however, did not address activist investor Elliott's calls to replace CEO Emma Walmsley on a private investor call. In July, Elliott urged the company to find a successor for Walmsley, whom it accused of mismanaging the demerger of GlaxoSmithKline's consumer business.